<DOC>
	<DOCNO>NCT02304757</DOCNO>
	<brief_summary>Postmenopausal woman differentiate thyroid cancer ( DTC ) take suppressive dos levothyroxine ( L-T4 ) think accelerate bone loss increase risk osteoporosis . Therefore , investigator try investigate effect 99Tc-MDP , calcium contain vitamin D alone fosamax ( alendronate sodium ) postmenopausal woman DTC decrease bone mineral density ( BMD ) .</brief_summary>
	<brief_title>99Tc-MDP Postmenopausal Women With Differentiated Thyroid Cancer Decreased Bone Mineral Density</brief_title>
	<detailed_description>Postmenopausal woman differentiate thyroid cancer ( DTC ) take suppressive dos levothyroxine ( L-T4 ) think accelerate bone loss increase risk osteoporosis . Therefore , investigator try investigate effect Technetium [ 99Tc ] Methylenediphosphonate ( 99Tc-MDP ) , calcium contain vitamin D alone fosamax ( alendronate sodium ) postmenopausal woman DTC decrease bone mineral density ( BMD ) . The investigator therefore randomize 58 patient slightly decrease BMD ( T Z-score lumbar spine neck region femur &gt; -2.0 SD dual energy X-ray ) take suppressive dos L-T4 treatment 99Tc-MDP ( low dose ) 10mg Intravenous drip every 1week ten week , every 2 week 22 week , every 1 month 4 month , calcium contain vitamin D alone . The control group , namely , 600mg calcium group contain vitamin D everyday . The investigator also randomize 148 patient obviously decrease BMD ( T Z-score lumbar spine neck region femur≤-2.0 SD ) take suppressive dos L-T4 treatment 99Tc-MDP ( high dose ) 15mg ivdripIntravenous drip every 1week ten week , every 2 week 22 week , every 1 month 4 month ( 99Tc-MDP ) , fosamax 70mg po 12 month . BMD spine hip measure dual energy x-ray absorptiometry bone densitometer . The spine measure posterior projection , result report total spine lumbar 1-4 . The hip measure standard projection , result report femoral neck , trochanter , total hip ; femoral neck choose represent site rich cortical bone , trochanter represent site relatively rich trabecular bone . Patients measurement serum alkaline phosphatase , bone turnover marker , osteocalcin , C-telopeptides type I collagen ( CTX ) , Type I N-procollagen terminal propeptide , etc every 3 , month 1 yr. We also evaluate bone pain numerical rating scale ( NRS ) , quality life Short Form-36 ( SF-36 ) score . All assay perform technician blind regard subject ' treatment assignment .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Methylene diphosphonate</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . Postmenopausal participant ; 2 . Histologically establish differentiate thyroid cancer ( DTC ) ; 3 . Total near total thyroidectomy radioiodine131 thyroid residual ablation ; 4 . Suppressive dos levothyroxine ( LT4 ) thyroid stimulate hormone ( ) ≦the low limit normal reference value ; 5 . Participants voluntarily participate In trial , sign informed consent . 1 . Secondary osteoporosis ; 2 . Osteoporosis receive treatment ; 3 . Severe liver kidney disease , bone marrow suppression ; 4 . Esophageal reflux gastritis ; 5 . Long term oral immunosuppressant , estrogen , selective estrogen receptor modulators .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>differentiate thyroid cancer</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>thyroid stimulate hormone suppression</keyword>
</DOC>